TY - JOUR T1 - Feasibility and Efficacy of Combination Chemotherapy with S-1 and Fractional Cisplatin for Advanced Gastric Cancer JF - Anticancer Research JO - Anticancer Res SP - 3759 LP - 3762 VL - 30 IS - 9 AU - TSUNEHIRO TAKAHASHI AU - YOSHIRO SAIKAWA AU - HIROMASA TAKAISHI AU - HIROYA TAKEUCHI AU - NORIHITO WADA AU - TAKASHI OYAMA AU - RIEKO NAKAMURA AU - YUKO KITAGAWA Y1 - 2010/09/01 UR - http://ar.iiarjournals.org/content/30/9/3759.abstract N2 - Background: There is a great need for effective outpatient chemotherapy for advanced gastric cancer in patients with good performance status. The present pilot study evaluated the use of combination chemotherapy with S-1 and fractional CDDP for unresectable–recurrent gastric cancer in an outpatient setting. Patients and Methods: A total of 41 patients with unresectable or recurrent gastric cancer were treated with this combination chemotherapy. S-1 was administered orally every day on days 1-28 and CDDP was infused on days 1, 15, and 29. Results: Thirty-six patients had measurable lesions and 19 patients had partial responses, resulting in an overall response rate of 52.8%. The median survival time was 494 days. There was no grade 4 haematological toxicity, no grade 3 or more non-haematological toxicity, and no treatment-related death. Conclusion: This combination chemotherapy has no serious toxicities in patients with unresectable and recurrent gastric cancer and can be used effectively in an outpatient setting. ER -